Understanding the role of chemotherapy for prostate cancer has advanced along two axes, better de®nition of endpoints, and biologic understanding of disease targets. Use of PSA as a surrogate endpoint makes possible the more rational design of phase III trials which will include survival and disease free intervals as an endpoint. Pain control has emerged as an important treatment endpoint through which more cost-effective care can be envisioned. Discovery of growth factor interactions with prostate cancer cells and the elucidation of apoptotic pathways have provided numerous new targets for biologic and chemotherapy of advanced disease.
Prior to this decade, chemotherapy of hormone refractory prostate cancer was disappointing. A review by Yagoda and Petrylak 1 of 26 studies performed between 1988 and 1991 demonstrated a response rate of only 8.7% (95% C.I. 6.4±9.0%). Improvements on this disappointing background are based on three factors: (1) newer therapeutic targets have emerged, such as the protein which modulate apoptosis, cytoplasmic microtubles, the nuclear matrix, peptide growth factors, and topisomerases; (2) evolution of new therapeutic endpoints such as pain control, quality of life, and cost effectiveness of competing forms of therapy; (3) better understanding of the biology of hormone refractory disease.
The mechanisms of anti-cancer drug action have recently focused on proteins which regulate apoptosis, or programmed cell death, which can be induced by growth factor deprivation, glucocorticoids, chemotherapy, and cellular proteins ( Figure 1 ). As shown in the ®gure, different pro-and anti-apoptotic pathways exist which have been identi®ed to play a major role in androgen-independent prostate cancer cell lines. For example, the anti-apoptotic protein Bcl-2 is expressed in two-thirds of androgen-independent human prostate cancers. 2 Similarly, mutant p53, the wild type of which is necessary for some types of chemotherapy-induced apoptosis, is present in 35% of androgen-independent prostate bone marrow metastatic specimens. As further insights are gained into these mechanisms, it is likely that newer drug stratagies will emerge which take advantage of the apoptotic and anti-apoptotic pathways.
Response assessment has also undergone important evolution during the 1990s. Because approximately 80% of patients have disease limited to bone, standard Phase II criteria have never provided the level of con®dence in chemotherapeutic effects found in other drug trials. In a multivariate analysis by Kelly, et al 3 of 110 patients treated on seven consecutive hormone refractory prostate trials at Memorial Sloan Kettering Cancer Center, PSA declines of ! 50% and a decline in the natural log of LDH were the most important factors in survival. However, since many chemotherapeutic agents can modulate PSA expression, this type of surrogate endpoint must be con®rmed by randomized Phase III trials with de®nite endpoints, such as overall survival and quality of life.
Recently, two randomized trials have demonstrated the superiority of mitoxantrone, a topisomerase II inhibitor, in combination with prednisone over prednisone alone. These studies, however, utilized control of bone pain as an endpoint and did not show a survival difference, partly due to the crossover design of the trials. Nevertheless, the overall cost of treating patients with the combination was less expensive than treatment with prednisone alone in an analysis of one study. 4, 5 Therefore, utilization of surrogate endpoints such as PSA, quality of life and pain scales has led to more cost-effective therapy of prostate cancer, which has helped to dispel the concept that chemotherapy is ineffective. Future trials will continue to focus on these surrogate endpoints, and give promise to the development of increasingly effective treatments which, at the very least, can improve quality of life and may eventually lead to the long-term goals of improved survival.
Among the newer regimens currently under study are combined anti-microtubule drug therapy (for example, estramustine, vinblastine, VP-16, and taxanes). Table 1 illustrates the response rates achieved with some of these regimens.
Other drugs under active investigation include suramin, a polysulfonated napthylurea, which interferes with the binding of peptide growth factors to their receptors, and the combination of ketoconazole plus doxorubicin, which has been shown to have important activity in terms of PSA responses. 6 
Interpretation of presentation and effects on prostate cancer management
The presentation by Petrylak illustrates some of the important challenges which remain to chemotherapists, as well as the opportunities which are emerging. While the use of surrogate endpoints such as PSA or pain control can be criticized from the standpoint of the traditional, rigid insistence on tumor shrinkage, we now realize that such responses can also be correlated with the equally important concepts of quality of life and cost effectiveness. This recognition will almost surely lead to re-evaluation of our goals in treating advanced hormone refractory prostate cancer and, in particular, the opportunity now exists to revisit some of the previously discarded approaches to this disease with these endpoints in mind. For example, with the establishment of mitoxantrone and prednisone as a`standard', approved by the FDA due to the superiority of the combination over prednisone alone, Phase III trials might be contemplated in which this standard was compared to a potentially even more cost effective regimen such as cyclophosphamide and prednisone. Similarly, the dramatic advances in our understanding of the biology of the disease, as pointed out by Petrylak, bring the possibility of new agents into the armamentarium almost immediately. While suramin may not have a suf®ciently attractive therapeutic index, the recent ®ndings which con®rm the importance of insulin-like growth factor and its binding protein in the overall biology of prostate cancer 7 will almost certainly lead to further attempts to ®nd agents with improved therapeutic indices that impact this pathway. The most important challenge for the large clinical trials organizations will be to utilize their resources both to explore the newer agents in well controlled Phase II trials that include the new endpoints, as well as to eventually explore these agents in appropriately selected subsets of patients at high risk with early prostate cancer. It now seems appropriate to apply some of the newer regimens in an adjuvant setting to subsets of patients at high risk for the eventual development of metastatic disease. Figure 1 p53 dependent mechanisms of apoptosis and drug resistance DNA damage.
